{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:11:41Z","timestamp":1769127101876,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T00:00:00Z","timestamp":1432166400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12933-015-0215-2","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T23:30:57Z","timestamp":1432078257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events"],"prefix":"10.1186","volume":"14","author":[{"given":"Julio","family":"Rosenstock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Neubacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Seck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Juergen","family":"Woerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odd Erik","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,21]]},"reference":[{"issue":"7533","key":"215_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","volume":"332","author":"R Huxley","year":"2006","unstructured":"Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73\u20138.","journal-title":"BMJ"},{"issue":"(Suppl 2)","key":"215_CR2","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1007\/PL00002934","volume":"44","author":"NJ Morrish","year":"2001","unstructured":"Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44((Suppl 2)):S14\u201321.","journal-title":"Diabetologia"},{"issue":"7134","key":"215_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","volume":"316","author":"RC Turner","year":"1998","unstructured":"Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823\u20138.","journal-title":"BMJ"},{"issue":"24","key":"215_CR4","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457\u201371.","journal-title":"N Engl J Med"},{"issue":"8","key":"215_CR5","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2337\/dc08-0167","volume":"31","author":"AD Rao","year":"2008","unstructured":"Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care. 2008;31(8):1672\u20138.","journal-title":"Diabetes Care"},{"issue":"Suppl","key":"215_CR6","first-page":"789","volume":"19","author":"CL Meinert","year":"1970","unstructured":"Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789\u2013830.","journal-title":"Diabetes"},{"issue":"12","key":"215_CR7","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.2337\/diacare.25.12.2244","volume":"25","author":"JA Johnson","year":"2002","unstructured":"Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25(12):2244\u20138.","journal-title":"Diabetes Care"},{"issue":"5","key":"215_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s00125-006-0176-9","volume":"49","author":"JM Evans","year":"2006","unstructured":"Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49(5):930\u20136.","journal-title":"Diabetologia"},{"issue":"3","key":"215_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1053\/euhj.1999.1999","volume":"21","author":"A Klamann","year":"2000","unstructured":"Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J. 2000;21(3):220\u20139.","journal-title":"Eur Heart J"},{"issue":"11","key":"215_CR10","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1210\/jc.2010-0449","volume":"95","author":"M Zeller","year":"2010","unstructured":"Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95(11):4993\u20135002.","journal-title":"J Clin Endocrinol Metab"},{"key":"215_CR11","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Diabetes Mellitus \u2014 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf. Accessed July 9, 2014."},{"issue":"14","key":"215_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"14","key":"215_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"key":"215_CR14","unstructured":"White W. Results from EXAMINE. Oral presentation at EASD 2013. http:\/\/www.cardiotimes.com\/documents\/powerpoints\/SLI064.ppt. Accessed May 26, 2015."},{"issue":"18","key":"215_CR15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 Randomized Trial. Circulation. 2014;130(18):1579\u201388.","journal-title":"Circulation"},{"issue":"1","key":"215_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1517\/13543780903463862","volume":"19","author":"CF Deacon","year":"2010","unstructured":"Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010;19(1):133\u201340.","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"215_CR17","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1517\/17425255.2011.628986","volume":"7","author":"AJ Scheen","year":"2011","unstructured":"Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol. 2011;7(12):1561\u201376.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"215_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1475-2840-11-3","volume":"11","author":"OE Johansen","year":"2012","unstructured":"Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3.","journal-title":"Cardiovasc Diabetol"},{"issue":"(Suppl 1)","key":"215_CR19","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1517\/14740338.2014.944862","volume":"13","author":"A Ceriello","year":"2014","unstructured":"Ceriello A, Sportiello L, Rafaniello C, Rossi F. DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin Drug Saf. 2014;13((Suppl 1)):S57\u201368.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"215_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3810\/pgm.2010.05.2138","volume":"122","author":"R Frederich","year":"2010","unstructured":"Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16\u201327.","journal-title":"Postgrad Med"},{"key":"215_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6823-10-7","volume":"10","author":"D Williams-Herman","year":"2010","unstructured":"Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"215_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1463-1326.2010.01215.x","volume":"12","author":"A Schweizer","year":"2010","unstructured":"Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"215_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1475-2840-12-3","volume":"12","author":"SS Engel","year":"2013","unstructured":"Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12:3.","journal-title":"Cardiovasc Diabetol"},{"issue":"4 Pt 1","key":"215_CR24","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/0002-8703(91)90694-D","volume":"121","author":"V Dzau","year":"1991","unstructured":"Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 Pt 1):1244\u201363.","journal-title":"Am Heart J"},{"issue":"24","key":"215_CR25","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1001\/jama.2013.282612","volume":"310","author":"SJ Lee","year":"2013","unstructured":"Lee SJ, Leipzig RM, Walter LC. Incorporating lag time to benefit into prevention decisions for older adults. JAMA. 2013;310(24):2609\u201310.","journal-title":"JAMA"},{"key":"215_CR26","unstructured":"McMurray J. Vildagliptin shows no adverse effect on ejection fraction in diabetic patients with HF. Presented at the Heart Failure Congress 2013, Lisbon, Portugal, May 25\u201328, 2013. abstract."},{"issue":"7","key":"215_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.numecd.2014.01.017","volume":"24","author":"M Monami","year":"2014","unstructured":"Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689\u201397.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"215_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/1755-5922.12075","volume":"32","author":"S Wu","year":"2014","unstructured":"Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147\u201358.","journal-title":"Cardiovasc Ther"},{"issue":"12_S","key":"215_CR29","doi-asserted-by":"publisher","first-page":"A117","DOI":"10.1016\/S0735-1097(14)60117-0","volume":"63","author":"F Zannad","year":"2014","unstructured":"Zannad F, Cannon C, Cushman W, Bakris G, Nissen S, Heller S, et al. Alogliptin in patients with type 2 diabetes after acute coronary syndromes: heart failure outcomes and cardiovascular safety in heart failure patients. J Am Coll Cardiol. 2014;63(12_S):A117.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"215_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1517\/14740338.2015.1006625","volume":"14","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14(4):505\u201324.","journal-title":"Expert Opin Drug Saf"},{"key":"215_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1475-2840-12-60","volume":"12","author":"M von Eynatten","year":"2013","unstructured":"von Eynatten M, Gong Y, Emser A, Woerle HJ. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol. 2013;12:60.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"215_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005752","volume":"4","author":"AC Tricco","year":"2014","unstructured":"Tricco AC, Antony J, Khan PA, Ghassemi M, Hamid JS, Ashoor H, et al. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open. 2014;4(12), e005752.","journal-title":"BMJ Open"},{"issue":"6","key":"215_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.ahj.2013.09.003","volume":"166","author":"JB Green","year":"2013","unstructured":"Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166(6):983\u20139.","journal-title":"Am Heart J"},{"issue":"4","key":"215_CR34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2337\/db12-0988","volume":"62","author":"V Darsalia","year":"2013","unstructured":"Darsalia V, Ortsater H, Olverling A, Darlof E, Wolbert P, Nystrom T, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2013;62(4):1289\u201396.","journal-title":"Diabetes"},{"key":"215_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12933-014-0110-2","volume":"13","author":"K Nakamura","year":"2014","unstructured":"Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13:110.","journal-title":"Cardiovasc Diabetol"},{"key":"215_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1475-2840-13-19","volume":"13","author":"C Ott","year":"2014","unstructured":"Ott C, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P, et al. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol. 2014;13:19.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"215_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1479164112475102","volume":"10","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2013;10(4):289\u2013301.","journal-title":"Diab Vasc Dis Res"},{"issue":"3","key":"215_CR38","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1479164115570301","volume":"12","author":"N Marx","year":"2015","unstructured":"Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes: CAROLINA\u00ae. Diab Vasc Dis Res. 2015;12(3):164\u201374.","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"215_CR39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1463-1326.2011.01391.x","volume":"13","author":"R Gomis","year":"2011","unstructured":"Gomis R, Espadero R-M, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study. Diabetes Obes Metab. 2011;13(7):653\u201361.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"215_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1463-1326.2010.01350.x","volume":"13","author":"S Del Prato","year":"2011","unstructured":"Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13(3):258\u201367.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"215_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","volume":"13","author":"MR Taskinen","year":"2011","unstructured":"Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65\u201374.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"215_CR42","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/j.1464-5491.2011.03387.x","volume":"28","author":"DR Owens","year":"2011","unstructured":"Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24\u00a0week randomised study. Diabet Med. 2011;28(11):1352\u201361.","journal-title":"Diabet Med"},{"issue":"8","key":"215_CR43","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.1463-1326.2009.01046.x","volume":"11","author":"T Heise","year":"2009","unstructured":"Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"215_CR44","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1463-1326.2011.01386.x","volume":"13","author":"T Forst","year":"2011","unstructured":"Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4\u00a0weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(6):542\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"215_CR45","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/j.1463-1326.2012.01586.x","volume":"14","author":"D Singh-Franco","year":"2012","unstructured":"Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2012;14(8):694\u2013708.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"215_CR46","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/j.1464-5491.2010.03131.x","volume":"27","author":"T Forst","year":"2010","unstructured":"Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med. 2010;27(12):1409\u201319.","journal-title":"Diabet Med"},{"issue":"1","key":"215_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s13300-012-0010-y","volume":"3","author":"T Rauch","year":"2012","unstructured":"Rauch T, Graefe-Mody U, Deacon CF, Ring A, Holst JJ, Woerle HJ, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther. 2012;3(1):10.","journal-title":"Diabetes Ther"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-015-0215-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-015-0215-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-015-0215-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-015-0215-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T13:35:59Z","timestamp":1630589759000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-015-0215-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,21]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["215"],"URL":"https:\/\/doi.org\/10.1186\/s12933-015-0215-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,21]]},"assertion":[{"value":"17 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"57"}}